Net revenue was stable YoY at BRL 571 million, with adjusted EBITDA down 10% YoY but net income up 6%. Portfolio adjustment via CSN divestment improved cash and reduced leverage, while operational efficiency and clinical excellence remain priorities.
Original document:
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.